Risk-based centralized data monitoring of clinical trials at the time of COVID-19 pandemic

被引:9
|
作者
Afroz, Most Alina [1 ]
Schwarber, Grant [2 ]
Bhuiyan, Mohammad Alfrad Nobel [2 ]
机构
[1] Begum Rokeya Univ, Dept Elect & Elect Engn, Rangpur, Bangladesh
[2] Medpace Inc, Dept Biostat, 5375 Medpace Way, Cincinnati, OH 45227 USA
关键词
Centralize data monitoring; Risk based data monitoring; DATA QUALITY;
D O I
10.1016/j.cct.2021.106368
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: COVID-19 pandemic caused several alarming challenges for clinical trials. On-site source data verification (SDV) in the multicenter clinical trial became difficult due to travel ban and social distancing. For multicenter clinical trials, centralized data monitoring is an efficient and cost-effective method of data monitoring. Centralized data monitoring reduces the risk of COVID-19 infections and provides additional capabilities compared to on-site monitoring. The key steps for on-site monitoring include identifying key risk factors and thresholds for the risk factors, developing a monitoring plan, following up the risk factors, and providing a management plan to mitigate the risk. Methods: For analysis purposes, we simulated data similar to our clinical trial data. We classified the data monitoring process into two groups, such as the Supervised analysis process, to follow each patient remotely by creating a dashboard and an Unsupervised analysis process to identify data discrepancy, data error, or data fraud. We conducted several risk-based statistical analysis techniques to avoid on-site source data verification to reduce time and cost, followed up with each patient remotely to maintain social distancing, and created a centralized data monitoring dashboard to ensure patient safety and maintain the data quality. Conclusion: Data monitoring in clinical trials is a mandatory process. A risk-based centralized data review process is cost-effective and helpful to ignore on-site data monitoring at the time of the pandemic. We summarized how different statistical methods could be implemented and explained in SAS to identify various data error or fabrication issues in multicenter clinical trials.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era
    Lee, Jinhee
    Shin, Han Wul
    Lee, Jun Young
    Kim, Jae Seok
    Yang, Jae Won
    Lee, Keum Hwa
    Kronbichler, Andreas
    Shin, Jae Il
    MEDICINA-LITHUANIA, 2020, 56 (06):
  • [42] Conducting dermatology clinical trials during the COVID-19 pandemic
    Sheriff, Tabrez
    Dickenson-Panas, Helen
    Murrell, Dedee F.
    CLINICS IN DERMATOLOGY, 2021, 39 (01) : 104 - 106
  • [43] Managing oncology clinical trials during COVID-19 pandemic
    Arai, Roberto J.
    Moniz, Camila M., V
    Chen, Andre T. C.
    Mak, Milena P.
    Chammas, Roger
    Hoff, Paulo M.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
  • [44] Collateral damage of COVID-19 pandemic on oncology clinical trials
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Alberts, Steve R.
    McWilliams, Robert
    Mahipal, Amit
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (06)
  • [45] Rethinking Clinical Trials Reform During the COVID-19 Pandemic
    Nabhan, Chadi
    Choueiri, Toni K.
    Mato, Anthony R.
    JAMA ONCOLOGY, 2020, 6 (09) : 1327 - 1329
  • [46] Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives
    Kotta, Sabna
    Aldawsari, Hibah Mubarak
    Badr-Eldin, Shaimaa M.
    Alhakamy, Nabil Abdulhafiz
    Md, Shadab
    Nair, Anroop B.
    Deb, Pran Kishore
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [47] Clinical Trials Before, During, and After COVID-19 Pandemic
    AlSaleh, Khalid A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (02): : 90 - 91
  • [48] Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic
    Shein-Chung Chow
    Wei Zhang
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1551 - 1556
  • [49] Risk-Based Quality Management: A Case for Centralized Monitoring
    Stansbury, Nicole
    Branco, Danilo
    Mcdavid, Cris
    Stewart, Jennifer
    Surdam, Kristin
    Olson, Nycole
    Perry, Joanne
    Liska, Jeremy
    Phillips, Linda
    Coogan, Amanda
    Adelfio, Anina
    Garson, Lauren
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2025, 59 (02) : 199 - 210
  • [50] Risk-Based Data Monitoring: Quality Control in Central Nervous System (CNS) Clinical Trials
    Cynthia McNamara
    Nina Engelhardt
    William Potter
    Christian Yavorsky
    Matthew Masotti
    Guillermo Di Clemente
    Therapeutic Innovation & Regulatory Science, 2019, 53 : 176 - 182